Sant Pau - Institut de Recerca

Main lines of research

Cognitive Impairment and Behavioural Dysfunctions in Parkinson Disease

Knowledge and detection of the neural correlates of cognitive performance in Parkinson disease using neurophysiological techniques (event-related brain cognitive potentials) and structural and functional neuroimaging (voxel-based morphometry, cortical thickness and spectroscopy).
Development of more sensitive tools for cognitive and functional assessment in Parkinson disease to detect subtle changes in cognitive performance and treatment response.
Prospective follow-up analysis of cognition and mood in patients with deep-brain stimulation of the subthalamic nucleus.
Physiological correlates and pharmacological approach to apathy in Parkinson disease and other movement disorders.
Neurophysiological and cognitive correlates of impulse control disorders in Parkinson disease and other movement disorders. Behavioral and pharmacological treatment.
Surgery and treatments of continuous infusion in Parkinson disease.
Follow-up and etiologic study of weight loss in patients treated with continuous infusion of intraduodenal levodopa.
Follow-up and etiologic study of weight loss in patients treated with continuous infusion of intraduodenal levodopa.

Essential Tremor and Other Movement Disorders

Molecular neuroimaging in essential tremor.
Clinical, neurophysiological and neuroimaging assessment of patients with FXTAS (fragile X-associated tremor/ataxia syndrome).

Translational Research – Parkinsonian Animal Models

Assessment of behavioural and cognitive modulations exerted by distinct antiparkinsonian drugs in murine models of Parkinson disease with lesions in particular neurotransmitter systems (dopaminergic and noradrenergic lesions).
Assessment of behavioural and cognitive traits of murine models of HD

Translational Research – Cell Models

Assessment of cell cultures of neurons derived of induced pluripotent cells (iPSCs) obtained from skin fibroblast as in vitro model for the modulation of key factors associated to both cognitive and neurotransmitter disturbances in Parkinson disease.

Huntington Disease

Study of the metabolic correlates (18-FDG PET) of disease progression from the pre-manifested to early-stages.
Study of the metabolic correlates (18-FDG PET) of apathy and depression in pre-manifested gene carriers.
Functional magnetic resonance imaging study of reward sensitivity in pre-manifested an early-stage Huntington’s disease.
Determination of the prevalence and clinical significance of neuropsychiatric features in Huntington’s disease.
Development of new instruments for cognitive and functional assessment in Huntington’s disease.
Prospective observational study of Huntington’s disease in a European cohort (Registry Study).
Molecular, clinical, behavioural and cognitive characterisation of the BACHD rat model of Huntington’s disease.
Collaboration in multicentre and Spanish coordinated projects:
- Relationship between intermediate alleles and clinical manifestations (PI: Esther Cubo, Burgos).
- Validation of the Spanish version of the Problem Behaviour Assessment Scale (PBA-S; PI: Jesús Ruiz, Barcelona).
- Study of dietary intake in Huntington’s disease (PI: Esther Cubo, Burgos).
- A multimodal neuroimaging approach to delineate emotional, motor and cognitive cortico-striatal pathways. IDIBELL (PI: Ruth de Diego-Balaguer, Barcelona).

Progresive Supranuclear Palsy

Development of a cognitive rating scale.
Development of a standarized eye movement evaluation.

Challenges

Cognitive and Behavioural Dysfunctions in Parkinson Disease

Study and understanding of the neural substrates of cognitive impairment in Parkinson disease so as to improve diagnostic and therapeutic approaches.
Development of specific tools to assess and track cognitive changes in Parkinson disease.

Huntington’s Disease

Study of the dynamics of mutant Htt protein aggregation and related neural and cognitive correlates along disease stages in Huntington’s disease.
Validation of new instruments to assess and track subtle cognitive changes in pre-manifested and early-stage Huntington’s disease population.

Essential Tremor and Other Movement Disorders

Genetic studies and genotype-phenotype correlations in essential tremor.
Development of new therapeutic interventions in essential tremor.
Neurochemical and structural neuroimaging studies on the pathophysiological bases of essential tremor.

Translational Research – Animal Models of Parkinsonism

Behavioural, physiological and pharmacological characterization of animal models of parkinsonism with combined dopaminergic and noradrenergic lesions.
Physiopathology of motor, cognitive and behavioural complications linked to antiparkinsonian drugs in animal models of parkinsonism.

Group coordination

KULISEVSKY BOJARSKI, JAIME FGS
jkulisevsky@santpau.cat

Members

Aracil Bolanos, Ignacio FGS
Berzosa Gonzalez, Irene IR
Burgos Renedo, Maria IR
Campolongo Perillo, Antonia FGS
Fernandez Vizuete, Cristina FGS
Garcia Sanchez, Carmen FGS
Gironell Carrero, Alexandre FGS
Horta Barba, Andrea IR
Martinez Horta, Saul Indra FGS
Pagonabarraga Mora, Javier FGS
Pascual Sedano, Berta Marta FGS
Perez Carasol, Laura IR
Perez Perez, Jesus FGS
Pla Sanchez, Monica IR
Pons Pons, Gracia IR
Rivas Asensio, Elisa Maria IR
Rodriguez-Antigüedad Muñoz, Jon IR
Rodriguez Salgueiro, Silvia IR
Ruiz Barrio, Iñigo IR
Salvat i Rovira, Nil IR
Sampedro Santalo, Frederic Vicenç FGS
Socarras Arredondo, Maria Andrea IR
Soler Almendros, Judit IR
Vazquez Oliver, Anna CIBERNED

Publications 2022

(JIF 2022)

Abdelnour C, Ferreira D, van de Beek M, Cedres N, Oppedal K, Cavallin L, Blanc F, Bousiges O, Wahlund LO, Pilotto A, Padovani A, Boada M, Pagonabarraga J, Kulisevsky J, Aarsland D, Lemstra AW, Westman E. Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. Alzheimers Research & Therapy. 2022; 14(1):14. DOI:10.1186/s13195-021-00946-w. PMID:35063023. IF:9 (Q1/1D). Document type: Article.
Aracil I, Martinez S, Gonzalez JM, Sampedro F, Perez J, Horta A, Campolongo A, Izquierdo C, Gomez B, Pagonabarraga J, Kulisevsky J. Structure and Dynamics of Large-Scale Cognitive Networks in Huntington’s Disease. MOVEMENT DISORDERS. 2022; 37(2). DOI:10.1002/mds.28839. PMID:34752656. IF:8,6 (Q1/1D). Document type: Article.
Aracil I, Sampedro F, Marin J, Horta A, Martinez S, Gonzalez JM, Perez J, Bejr H, Pascual B, Boti M, Campolongo A, Izquierdo C, Gironell A, Gomez B, Kulisevsky J, Pagonabarraga J. Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson’s disease mild cognitive impairment. Brain Imaging and Behavior. 2022; 16(2). DOI:10.1007/s11682-021-00543-3. PMID:34553331. IF:3,2 (Q2/5D). Document type: Article.
Aretouli E, Chondrogiorgi M, Dede O, Koutsonida M, Lafi C, Konstantinopoulou E, Kulisevsky J, Kosmidis MH, Konitsiotis S. The Parkinson’s Disease-Cognitive Rating Scale: Greek Normative Data, Clinical Utility and Cultural Considerations. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY. 2022; 35(5):08919887211049110. DOI:10.1177/08919887211049110. PMID:34663111. IF:2,6 (Q3/7D). Document type: Article.
Asl AM, Mehdizadeh M, Kulisevsky J, Sabet A, Sharabiani P, Mehdizadeh H, Ashayeri H, Taghizadeh G. Reliability, validity, and diagnostic accuracy of Parkinson’s Disease-Cognitive Rating Scale in Iranian patients with idiopathic Parkinson’s disease. DISABILITY AND REHABILITATION. 2022; 44(10). DOI:10.1080/09638288.2020.1813337. PMID:32924645. IF:2,2 (Q2/4D). Document type: Article.
Bach L, Boccalatte F, DeRosa A, Devos D, Garcia C, Inglese M, Droby A. Functional changes in prefrontal cortex following frequency-specific training. Scientific Reports. 2022; 12(1):20316. DOI:10.1038/s41598-022-24088-7. PMID:36434008. IF:4,6 (Q2/3D). Document type: Article.
Bejr H, Martinez S, Pagonabarraga J, Marin J, Horta A, Sampedro F, Aracil I, Perez J, Campolongo A, Izquierdo C, Pascual B, Kulisevsky J. The role of attentional control over interference in minor hallucinations in Parkinson’s disease. PARKINSONISM & RELATED DISORDERS. 2022; 102. DOI:10.1016/j.parkreldis.2022.07.009. PMID:35987038. IF:4,1 (Q2/3D). Document type: Article.
Calabria M, Garcia C, Grunden N, Pons C, Arroyo JA, Gomez B, Garcia M, Belvis R, Morollon N, Igual JV, Mur I, Pomar V, Domingo P. Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms. JOURNAL OF NEUROLOGY. 2022; 269(8). DOI:10.1007/s00415-022-11141-8. PMID:35488918. IF:6 (Q1/2D). Document type: Article.
De la Riva P, Rodriguez J, Gomez V, Arenaza G, Gorostidi A, Diez N, De Arce A, Martinez M, Gonzalez F, Luttich A, Garmendia E, Sola A, Larrea JA, Bergareche A, Sobrino T. Endothelial NO synthase 786T/T polymorphism increases hemorrhagic transformation after endovascular thrombectomy. NITRIC OXIDE-BIOLOGY AND CHEMISTRY. 2022; 129. DOI:10.1016/j.niox.2022.08.006. PMID:36067953. IF:3,9 (Q2/5D). Document type: Article.
De Paepe AE, Garcia C, Martinez S, Perez JP, Kulisevsky J, Rodriguez N, Vaquer I, Subira S, Calopa M, Santacruz P, Munoz E, Mareca C, Ruiz J, De Diego R, Camara E. Delineating apathy profiles in Huntington’s disease with the short-Lille Apathy Rating Scale. PARKINSONISM & RELATED DISORDERS. 2022; 105. DOI:10.1016/j.parkreldis.2022.10.025. PMID:36395542. IF:4,1 (Q2/3D). Document type: Article.
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Delannoy PG, Poewe W, Compta Y, Pavese N, Ruzicka E, Dusek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory F, Walter U, de Bie R, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, et al. Trial of Deferiprone in Parkinson’s Disease. NEW ENGLAND JOURNAL OF MEDICINE. 2022; 387(22). DOI:10.1056/NEJMoa2209254. PMID:36449420. IF:158,5 (Q1/1D). Document type: Article.
Ferraro PM, Spotorno N, Finegan E, Sampedro F, Caso F. Editorial: Genotype-phenotype correlations in neurodegenerative diseases: From clinical features to neuroimaging signatures. Frontiers in Neurology. 2022; 13:1100953. DOI:10.3389/fneur.2022.1100953. PMID:36588898. IF:3,4 (Q2/5D). Document type: Editorial material.
Ferreira JJ, Rodrigues FB, Duarte GS, Mestre TA, Bachoud AC, Bentivoglio AR, Burgunder JM, Cardoso F, Claassen DO, Landwehrmeyer GB, Kulisevsky J, Nirenberg MJ, Rosser A, Roth J, Seppi K, Slawek J, Furr E, Tabrizi SJ, Walker FO, Vandenberghe W, Costa J, Sampaio C. An MDS Evidence-Based Review on Treatments for Huntington’s Disease. MOVEMENT DISORDERS. 2022; 37(1). DOI:10.1002/mds.28855. PMID:34842303. IF:8,6 (Q1/1D). Document type: Review.
Garcia C, Calabria M, Grunden N, Pons C, Arroyo JA, Gomez B, Lleo A, Alcolea D, Belvis R, Morollon N, Mur I, Pomar V, Domingo P. Neuropsychological deficits in patients with cognitive complaints after COVID-19. Brain and Behavior. 2022; 12(3):e2508. DOI:10.1002/brb3.2508. PMID:35137561. IF:3,1 (Q2/3D). Document type: Article.
Garcia DS, Roca LG, Fonticoba TD, Bartolome CC, Rios LN, Canfield H, Gonzalez JMP, Miro CM, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Vara JH, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Mayordomo VG, Nogueira V, Puente V, Garcia JD, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, Padilla FC, et al. [Kulisevsky J]. Constipation Predicts Cognitive Decline in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. Journal of Parkinsons Disease. 2022; 12(1). DOI:10.3233/JPD-212868. PMID:34602501. IF:5,2 (Q1/3D). Document type: Article.
Garcia DS, Sauco MA, Calopa M, Carrillo F, Sevilla FE, Freire E, Ramos RG, Kulisevsky J, Esteban JCG, Legarda I, Luquin M, Castrillo JCM, Martinez P, Martinez I, Mir P, Ignacio AS. MNCD: A New Tool for Classifying Parkinson’s Disease in Daily Clinical Practice. 2022; 12(1):55. DOI:10.3390/diagnostics12010055. PMID:35054222. IF:3,6 (Q2/4D). Document type: Article.
Horta A, Martinez S, Perez J, Sampedro F, Puig A, Pagonabarraga J, Kulisevsky J. Measuring the functional impact of cognitive impairment in Huntington’s disease. JOURNAL OF NEUROLOGY. 2022; 269(7). DOI:10.1007/s00415-021-10955-2. PMID:35061089. IF:6 (Q1/2D). Document type: Article.
Illan I, Nigro S, VandeVrede L, Falgas N, Heuer HW, Painous C, Compta Y, Marti MJ, Montal V, Pagonabarraga J, Kulisevsky J, Lleo A, Fortea J, Logroscino G, Quattrone A, Quattrone A, Perry DC, Gorno ML, Rosen HJ, Grinberg LT, Spina S, La Joie R, Rabinovici GD, Miller BL, Rojas JC, Seeley WW, Boxer AL. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open. 2022; 5(4):e229588. DOI:10.1001/jamanetworkopen.2022.9588. PMID:35486397. IF:13,8 (Q1/1D). Document type: Article.
Kulisevsky J, Martinez S, Campolongo A, Pascual B, Marin J, Bejr H, Aracil I, Horta A, Puig A, Pagonabarraga J. A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson’s Disease. Frontiers in Neurology. 2022; 13:866502. DOI:10.3389/fneur.2022.866502. PMID:35720066. IF:3,4 (Q2/5D). Document type: Article.
Kulisevsky J. Pharmacological management of Parkinson’s disease motor symptoms: update and recommendations from an expert. REVISTA DE NEUROLOGIA. 2022; 75(s04):S1-S10. DOI:10.33588/rn.75s04.2022217. PMID:36342310. IF:1,2 (Q4/10D). Document type: Review.
Marin J, Martinez S, Pagonabarraga J, Horta A, Aracil I, Bejr H, Sampedro F, Campolongo A, Kulisevsky J. Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers. ANNALS OF NEUROLOGY. 2022; 92(6). DOI:10.1002/ana.26486. PMID:36054656. IF:11,2 (Q1/1D). Document type: Article.
Mauricio D, Vlacho B, de la Puente JB, Mundet X, Real J, Kulisevsky J, Ortega E, Castelblanco E, Julve J, Franch J. Associations Between Diabetic Retinopathy and Parkinson’s Disease: Results From the Catalonian Primary Care Cohort Study. Frontiers in Medicine. 2022; 8:800973. DOI:10.3389/fmed.2021.800973. PMID:35118094. IF:8,1 (Q1/2D). Document type: Article.
Pagonabarraga J, Perez R, Bejr H, Marin J, Horta A, Martinez S, Aracil I, Sampedro F, Campolongo A, Rivas E, Puig A, Ruiz I, Perez J, Pascual B, Kulisevsky J. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson’s disease. PARKINSONISM & RELATED DISORDERS. 2022; 105. DOI:10.1016/j.parkreldis.2022.05.020. PMID:35752549. IF:4,1 (Q2/3D). Document type: Article.
Pérez C, Hernández J, Caballol N, Bayes À, Buongiorno M, Lopez N, Gironell A, López J, Martínez JC, Sauco A, López L, Escalante S, Pérez DA, Rodríguez A, The MoMoPa G. Comparison of the Results of a Parkinson’s Holter Monitor With Patient Diaries, in Real Conditions of Use: A Sub-analysis of the MoMoPa-EC Clinical Trial. Frontiers in Neurology. 2022; 13:835249. DOI:10.3389/fneur.2022.835249. PMID:35651347. IF:3,4 (Q2/5D). Document type: Article.
Pou MA, Orfila F, Pagonabarraga J, Ferrer S, Corominas H, Diaz C. Le risque de maladie de Parkinson dans une population méditerranéenne de patients goutteux : étude cas-témoins. Revue Du Rhumatisme (edition Francaise). 2022; 89(6). DOI:10.1016/j.rhum.2022.09.019. Document type: Article.
Pou MA, Orfila F, Pagonabarraga J, Ferrer S, Corominas H, Diaz C. Risk of Parkinson’s disease in a gout Mediterranean population: A case-control study. JOINT BONE SPINE. 2022; 89(6):105402. DOI:10.1016/j.jbspin.2022.105402. PMID:35504516. IF:4,2 (Q2/4D). Document type: Article.
Rodríguez F, Beltrán Á, Chico JL, Parra P, Baena B, Pagonabarraga J, Pérez P, Pareés I, López JL, Martínez JC, Alonso A. Efficacy and safety of high doses of safinamide in advanced Parkinson disease. PARKINSONISM & RELATED DISORDERS. 2022; 97. DOI:10.1016/j.parkreldis.2022.03.010. PMID:35344893. IF:4,1 (Q2/3D). Document type: Letter.
Rosas I, Morís G, Coto E, Blázquez M, Suárez E, García C, Martínez C, Herrera ID, Pérez S, Álvarez V, Menéndez M, Adarmes AD, Aguilar M, Alvarez I, Barrero FJ, Bergareche JA, Bonilla M, Botía JA, Boungiorno MT, Buiza D, Cámara A, Carrillo F, Cerdan D, Clarimón J, Compta Y, Diez M, Dols-Icardo O, de Fabregues O, Cartagena PS, Duarte J, Duran R, Escamilla F, et al. [Kulisevsky J, Pagonabarraga J, Pascual Sedano B, ]. Smoking is associated with age at disease onset in Parkinson’s disease. PARKINSONISM & RELATED DISORDERS. 2022; 97. DOI:10.1016/j.parkreldis.2022.03.005. PMID:35364453. IF:4,1 (Q2/3D). Document type: Article.
Ruiz I, Horta A, Illan I, Kulisevsky J, Pagonabarraga J. Genotype-Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities. Frontiers in Neurology. 2022; 13:861585. DOI:10.3389/fneur.2022.861585. PMID:35557621. IF:3,4 (Q2/5D). Document type: Review.
Saiz M, Gil C, Diez M, Martinez SI, Santalo FS, Calvo S, Alonso E, Rinones E, Aguado L, Mariscal N, Munoz I, Pineiro D, Rivadeneyra J, Cubo E. Polymorphisms in the oxytocin receptor and their association with apathy and impaired social cognition in Huntington’s disease. NEUROLOGICAL SCIENCES. 2022; 43(10). DOI:10.1007/s10072-022-06226-1. PMID:35725858. IF:3,3 (Q2/5D). Document type: Article.
Sampedro F, Aracil I, Farres C, Soler J, Schmidt C, Elices M, Pomarol E, Salvador R, Vega D, Pascual JC. A Functional Connectivity Study to Investigate the Role of the Right Anterior Insula in Modulating Emotional Dysfunction in Borderline Personality Disorder. PSYCHOSOMATIC MEDICINE. 2022; 84(1). DOI:10.1097/PSY.0000000000001019. PMID:34611112. IF:3,3 (Q2/4D). Document type: Article.
Sampedro F, Camara E, Kulisevsky J. Editorial: Neuroimaging of Cognitive and Neuropsychiatric Symptoms in Movement Disorders. Frontiers in Neurology. 2022; 13:843440. DOI:10.3389/fneur.2022.843440. PMID:35173676. IF:3,4 (Q2/5D). Document type: Editorial material.
Sampedro F, Kulisevsky J. Intracortical surface-based MR diffusivity to investigate neurologic and psychiatric disorders: a review. JOURNAL OF NEUROIMAGING. 2022; 32(1). DOI:10.1111/jon.12930. PMID:34506674. IF:2,4 (Q3/6D). Document type: Review.
Sampedro F, Martinez S, Horta A, Grothe MJ, Labrador MA, Jesus S, Adarmes A, Carrillo F, Puig A, Lora FR, Barbera MA, Pastor P, Arroyo SE, Vila BS, Foraster AC, Martinez JR, Padilla FC, Morlans MP, Aramburu IG, Ceberio JI, Vara JH, de Fabregues O, de Deus T, Avila A, Martinez JC, Bejr H, Campolongo A, Pascual B, Martinez P, Santos D, Mir P, Kulisevsky J. Increased homocysteine levels correlate with cortical structural damage in Parkinson’s disease. JOURNAL OF THE NEUROLOGICAL SCIENCES. 2022; 434:120148. DOI:10.1016/j.jns.2022.120148. PMID:35085959. IF:4,4 (Q2/3D). Document type: Article.
Sampedro F, Martinez S, Horta A, Grothe MJ, Labrador MA, Jesus S, Adarmes A, Carrillo F, Puig A, Roldan F, Aguilar M, Pastor P, Arroyo SE, Vila BS, Cots A, Ruiz J, Carrillo F, Pueyo M, Gonzalez I, Infante J, Hernandez J, de Fabregues O, Fonticoba TD, Avila A, Martinez JC, Bejr H, Campolongo A, Pascual B, Martinez P, Santos D, Mir P, Garcia PJ, Kulisevsky J. Clinical and structural brain correlates of hypomimia in early-stage Parkinson’s disease. EUROPEAN JOURNAL OF NEUROLOGY. 2022; 29(12). DOI:10.1111/ene.15513. PMID:35852918. IF:5,1 (Q1/2D). Document type: Article.
Sampedro F, Martínez S, Kulisevsky J. Response to letter: “Association of elevated blood homocysteine with cognitive decline in early, untreated Parkinson’s disease”. JOURNAL OF THE NEUROLOGICAL SCIENCES. 2022; 438:120272. DOI:10.1016/j.jns.2022.120272. PMID:35576640. IF:4,4 (Q2/3D). Document type: Letter.
Sampedro F, Martinez S, Marin J, Pagonabarraga J, Kulisevsky J. Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson’s Disease. Journal of Parkinsons Disease. 2022; 12(5). DOI:10.3233/JPD-223223. PMID:35491803. IF:5,2 (Q1/3D). Document type: Article.
Sampedro F, Martinez S, Perez J, Perez R, Horta A, Campolongo A, Izquierdo C, Aracil I, Rivas E, Puig A, Pagonabarraga J, Gomez B, Kulisevsky J. Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntington’s Disease. Clinical Neuroradiology. 2022; 32(4). DOI:10.1007/s00062-022-01150-5. PMID:35238950. IF:2,8 (Q2/5D). Document type: Article.
Santos D, Canfield H, de Deus T, Cores C, Naya L, García L, Martínez C, Jesús S, Aguilar M, Pastor P, Cosgaya M, García J, Caballol N, Legarda I, Hernández J, Cabo I, López L, González I, Ávila MA, Gómez V, Nogueira V, Puente V, Dotor J, Borrué C, Solano B, Álvarez M, Vela L, Escalante S, Cubo E, Carrillo F, Martínez JC, Sánchez P, Alonso MG, López N, Gastón I, Kulisevsky J, et al. Parkinson’s Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Parkinsons Disease. 2022; 12(3). DOI:10.3233/JPD-213004. PMID:34957949. IF:5,2 (Q1/3D). Document type: Article.
Santos D, Fonticoba TD, Bartolome CC, Alvarado M, Panceiras MJF, Castro ES, Canfield H, Miro CM, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Vara JH, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Mayordomo VG, Nogueira V, Puente V, Garcia JD, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, et al. [Kulisevsky J]. Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson’s disease patients. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2022; 37(6):GPS5761. DOI:10.1002/gps.5761. PMID:35633051. IF:4 (Q2/5D). Document type: Article.
Santos D, Fonticoba TD, Bartolome CC, Painceiras MJF, Castro ES, Canfield H, Miro CM, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Hernandez J, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Mayordomo VG, Nogueira V, Puente V, Garcia JD, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, Padilla FC, et al. [Kulisevsky J]. Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson’s Disease Patients: A 2-Year Follow-Up Study. 2022; 12(5):1147. DOI:10.3390/diagnostics12051147. PMID:35626303. IF:3,6 (Q2/4D). Document type: Article.
Stocchi F, Antonini A, Berg D, Bergmans B, Jost W, Katzenschlager R, Kulisevsky J, Odin P, Valldeoriola F, Chaudhuri KR. Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus. npj Parkinsons Disease. 2022; 8(1):17. DOI:10.1038/s41531-022-00277-z. PMID:35190544. IF:8,7 (Q1/1D). Document type: Article.
Valle N, Pérez R, Chiva G, Belbin O, Serrano S, Sirisi S, González AC, Giró O, Sánchez É, Dols O, Alcolea D, Carmona M, Jimenez A, Lleó A, Fortea J, Iulita MF. Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma. Jove-Journal of Visualized Experiments. 2022; 2022(186):e64107. DOI:10.3791/64107. PMID:35993755. IF:1,2 (Q3/8D). Document type: Article.

Publications 2021

Abbruzzese G, Kulisevsky J, Bergmans B, Gomez JC, Kagi G, Raw J, Stefani A, Warnecke T, Jost WH, SYNAPSES Study Investigators GRP. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. Journal of Parkinsons Disease. 2021; 11(1). DOI:10.3233/JPD-202224. PMID:33104040. IF: 5,520
Aracil I, Sampedro F, Pujol J, Soriano C, Gonzalez JM, Kulisevsky J, Pagonabarraga J. The impact of dopaminergic treatment over cognitive networks in Parkinson’s disease: Stemming the tide?. HUMAN BRAIN MAPPING. 2021; 42(17). DOI:10.1002/hbm.25650. PMID:34510640. IF: 5,399
Bejr-Kasem H, Sampedro F, Marín-Lahoz J, Martínez-Horta S, Pagonabarraga J, Kulisevsky J. Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson’s disease. European Journal of Neurology. 2021;28(2):438-447. DOI:10.1111/ene.14576. PMID: 33032389. IF: 6,288
Bernasconi F, Blondiaux E, Potheegadoo J, Stripeikyte G, Pagonabarraga J, Bejr H, Bassolino M, Akselrod M, Martinez S, Sampedro F, Hara M, Horvath J, Franza M, Konik S, Bereau M, Ghika JA, Burkhard PR, Van de Ville D, Faivre N, Rognini G, Krack P, Kulisevsky J, Blanke O. Robot-induced hallucinations in Parkinson’s disease depend on altered sensorimotor processing in fronto-temporal network. Science Translational Medicine. 2021; 13(591):eabc8362. DOI:10.1126/scitranslmed.abc8362. PMID:33910980. IF: 19,319
Blauwendraat C, Iwaki H, Makarious MB, Bandres S, Leonard HL, Grenn FP, Lake J, Krohn L, Tan M, Kim JJ, Gibbs JR, Hernandez DG, Ruskey JA, Pihlstrom L, Toft M, van JJ, Marinus J, Schulte C, Brockmann K, Sharma M, Siitonen A, Majamaa K, Eerola J, Tienari PJ, Grosset DG, Lesage S, Corvol JC, Brice A, Wood N, et al. [Clarimón J, Dols O, Kulisevsky J, Pagonabarraga J]. Investigation of Autosomal Genetic Sex Differences in Parkinson’s Disease. ANNALS OF NEUROLOGY. 2021; 90(1). DOI:10.1002/ana.26090. PMID:33901317. IF: 11,274
Calabria M, Perez JP, Martinez S, Horta A, Carceller M, Kulisevsky J, Costa A. Language reconfiguration in bilinguals A study with Huntington’s disease patients. Linguistic Approaches to Bilingualism. 2021; 11(4). DOI:10.1075/lab.18022.cal. IF: 1,815
Chen ZB, Zhang D, Reynolds RH, Gustavsson EK, Garcia S, D’Sa K, Fairbrother A, Vandrovcova J, Hardy J, Houlden H, Taliun S, Botia J, Ryten M, Clarimón J, Dols O, Kulisevsky J, Pagonabarraga J, Int Parkinson’s Dis Genomics C. Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage. Nature Communications. 2021; 12(1):2076. DOI:10.1038/s41467-021-22262-5. PMID:33824317. IF: 17,694
De Paepe AE, Ara A, Garcia C, Martinez S, Perez J, Kulisevsky J, Rodriguez N, Vaquer I, Subira S, Calopa M, Munoz E, Santacruz P, Ruiz J, Mareca C, de Diego R, Camara E. Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington’s Disease. MOVEMENT DISORDERS. 2021; 36(9). DOI:10.1002/mds.28638. PMID:33998063. IF: 9,698
Diez M, Houle G, Ortega S, Bandres S, Alvarez I, Carcel M, Ibanez L, Fernandez MV, Budde JP, Trotta JR, Tonda R, Chong JX, Bamshad MJ, Nickerson DA, Aguilar M, Tartari JP, Gironell A, Garcia E, Agundez J, Alonso H, Jimenez FJ, Fernandez M, Valldeoriola F, Marti MJ, Tolosa E, Coria F, Pastor MA, Vilarino C, Rajput A, Dion PA, Cruchaga C, Rouleau GA, Pastor P, U. Exome-wide rare variant analysis in familial essential tremor. PARKINSONISM & RELATED DISORDERS. 2021; 82. DOI:10.1016/j.parkreldis.2020.11.021. PMID:33279834. IF: 4,402
Gaig C, Compta Y, Heidbreder A, Marti MJ, Titulaer MJ, Crijnen Y, Hogl B, Lewerenz J, Erro ME, Garcia JC, Nigro P, Tambasco N, Patalong M, Erdler M, Macher S, Berger E, Hoftberger R, Geis C, Hutterer M, Milan A, Martin A, Manzanares LL, Quintas S, Hoglinger GU, Mohn N, Schoberl F, Thaler FS, Asioli GM, Provini F, Plazzi G, Berganzo K, Blaabjerg M, et al. [Perez JP]. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. NEUROLOGY. 2021; 97(14). DOI:10.1212/WNL.0000000000012639. PMID:34380749. IF: 11,800
Garcia R, Santos D, Alonso A, Alvarez M, Ares B, Avila A, Caballol N, Carrillo F, Sevilla FE, Freire E, Esteban JCG, Legarda I, Manzanares LL, Valdes EL, Martinez I, Mata M, Parees I, Pascual B, Mir P, Castrillo JCM. Management of Parkinson’s disease and other movement disorders in woman of childbearing age: Part 1. NEUROLOGIA. 2021; 36(2). DOI:10.1016/j.nrl.2020.05.010. PMID:32718872. IF: 5,486
Garcia R, Santos D, Alonso A, Alvarez M, Ares B, Avila A, Caballol N, Carrillo F, Sevilla FE, Freire E, Esteban JCG, Legarda I, Manzanares LL, Valdes EL, Martinez I, Mata M, Parees I, Pascual B, Castrillo JCM, Mir P. Management of Parkinson’s disease and other movement disorders in women of childbearing age: Part 2. NEUROLOGIA. 2021; 36(2). DOI:10.1016/j.nrl.2020.05.012. PMID:32980194. IF: 5,486
Gialluisi A, Reccia MG, Modugno N, Nutile T, Lombardi A, Di LG, Pietracupa S, Ruggiero D, Scala S, Gambardella S, Iacoviello L, Gianfrancesco F, Acampora D, D’Esposito M, Simeone A, Ciullo M, Esposito T, Kulisevsky J, Pagonabarraga J, Int Parkinsons Dis Genomics C. Identification of sixteen novel candidate genes for late onset Parkinson’s disease. Molecular Neurodegeneration. 2021; 16(1):35. DOI:10.1186/s13024-021-00455-2. PMID:34148545. IF: 18,879
Grothe MJ, Labrador MA, Jesus S, Macias D, Adarmes A, Carrillo F, Camacho EI, Franco P, Lora FR, Martin JF, Barbera MA, Pastor P, Arroyo SE, Vila BS, Foraster AC, Martinez JR, Padilla FC, Morlans MP, Aramburu IG, Ceberio JI, Vara JH, de Fabregues O, Fonticoba TD, Pascual B, Kulisevsky J, Martinez P, Santos D, Mir P. In vivo cholinergic basal forebrain degeneration and cognition in Parkinson’s disease: Imaging results from the COPPADIS study. PARKINSONISM & RELATED DISORDERS. 2021; 88. DOI:10.1016/j.parkreldis.2021.05.027. PMID:34144230. IF: 4,402
Horta A, Pagonabarraga J, Martinez S, Busteed L, Pascual B, Illan I, Marin J, Aracil I, Perez J, Sampedro F, Bejr H, Kulisevsky J. Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. JOURNAL OF NEUROLOGY. 2021; 268(9). DOI:10.1007/s00415-021-10511-y. PMID:33704556. IF: 6,682
Jost ST, Visser V, Rizos A, Loehrer PA, Silverdale M, Evans J, Samuel M, Petry JN, Sauerbier A, Gronostay A, Barbe MT, Fink GR, Ashkan K, Antonini A, Martinez P, Chaudhuri KR, Timmermann L, Dafsari HS, Pagonabarraga J, Walker RW. Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. npj Parkinsons Disease. 2021; 7(1):48. DOI:10.1038/s41531-021-00174-x. PMID:34103534. IF: 9,304
Kia DA, Zhang D, Guelfi S, Manzoni C, Hubbard L, Reynolds RH, Botia J, Ryten M, Ferrari R, Lewis PA, Williams N, Trabzuni D, Hardy J, Wood NW, Clarimón J, Dols O, Kulisevsky J, Pagonabarraga J, United B, Int Parkinsons Dis G. Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurology. 2021; 78(4). DOI:10.1001/jamaneurol.2020.5257. PMID:33523105. IF: 29,907
Lage C, Lopez S, Bejanin A, Kazimierczak M, Aracil I, Calvo A, Pozueta A, Garcia M, Fernandez A, Bravo M, Jimenez J, Banzo I, Irure J, Pegueroles J, Illan I, Fortea J, Rodriguez E, Lleo A, Garcia CE, Sanchez P. Distinctive Oculomotor Behaviors in Alzheimer’s Disease and Frontotemporal Dementia. Frontiers in Aging Neuroscience. 2021; 12:603790. DOI:10.3389/fnagi.2020.603790. PMID:33613262. IF: 5,702
Leon P, Pagonabarraga J, Moris J, Martinez S, Marin J, Horta A, Bejr H, Kulisevsky J, Rodriguez A. Neural signatures of predictive language processing in Parkinson’s disease with and without mild cognitive impairment. CORTEX. 2021; 141. DOI:10.1016/j.cortex.2021.03.032. PMID:34049254. IF: 4,644
Martinez S, Bejr H, Horta A, Pascual B, Santos D, De Deus T, Jesus S, Aguilar M, Planellas L, Garcia J, Caballol N, Vives B, Hernandez J, Cabo I, Lopez L, Gonzalez I, Avila MA, Catalan MJ, Lopez LM, Puente V, Garcia JM, Borrue C, Solano B, Alvarez M, Vela L, Escalante S, Cubo E, Carrillo F, Martinez JC, Sanchez P, Alonso MG, Lopez N, Gaston I, et al. [Kulisevsky J]. Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson’s disease. BMC Neurology. 2021; 21(1):477. DOI:10.1186/s12883-021-02485-1. PMID:34879838. IF: 2,903
Martinez S, Ivanir E, Perrinjaquet T, Keuter MH, Kulisevsky J. Effects of a Green Oat Herb Extract on Cognitive Performance and Neurophysiological Activity: A Randomized Double-Blind Placebo-Controlled Study. Frontiers in Neuroscience. 2021; 15:748188. DOI:10.3389/fnins.2021.748188. PMID:34658781. IF: 5,152
Martinez-Horta S, Sampedro F, Horta-Barba A, Perez-Perez J, Pagonabarraga J, Gomez-Anson B, Kulisevsky J. Structural brain correlates of irritability and aggression in early manifest Huntington’s disease. Brain Imaging and Behavior. 2021;15(1):107-113. DOI:10.1007/s11682-019-00237-x. PMID: 31898092. IF: 3,224
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A, PASADENA I, Bejr H, Bojarsky JK, Prasinezumab GRP. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson’s Disease (PASADENA): Rationale, Design, and Baseline Data. Frontiers in Neurology. 2021; 12:705407. DOI:10.3389/fneur.2021.705407. PMID:34659081. IF: 4,086
Pagonabarraga J, Horta A, Busteed L, Bejr H, Illan I, Aracil I, Marin J, Pascual B, Perez J, Campolongo A, Izquierdo C, Martinez S, Sampedro F, Kulisevsky J. Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy. PARKINSONISM & RELATED DISORDERS. 2021; 85. DOI:10.1016/j.parkreldis.2021.03.002. PMID:33744691. IF: 4,402
Pagonabarraga J, Tinazzi M, Caccia C, Jost WH. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson’s disease: Clinical cases and a review of the literature. JOURNAL OF CLINICAL NEUROSCIENCE. 2021; 90. DOI:10.1016/j.jocn.2021.05.056. PMID:34275546. IF: 2,116
Perez A, Giraldo DM, Rios J, Munoz E, Compta Y, Marti MJ, Pagonabarraga J. Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry. Journal of Parkinsons Disease. 2021; 11(2). DOI:10.3233/JPD-202332. PMID:33492245. IF: 5,520
Pezzoli S, Sanchez R, Solanes A, Kempton MJ, Bandmann O, Il J, Cagnin A, Goldman JG, Merkitch D, Firbank MJ, Taylor JP, Pagonabarraga J, Kulisevsky J, Blanc F, Verdolini N, Venneri A, Radua J. Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson’s disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS. 2021; 128. DOI:10.1016/j.neubiorev.2021.06.030. PMID:34171324. IF: 9,052
Rodriguez A, Hernandez J, Minarro A, Perez C, Bayes A, Martinez JC, Perez DA, Gironell A, Monitoring Parkinsons Patients M. Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson’s symptoms against other clinical monitoring methods: study protocol. BMJ Open. 2021; 11(7):e045272. DOI:10.1136/bmjopen-2020-045272. PMID:34281918. IF: 3,006
Sampedro F, Farres C, Soler J, Elices M, Schmidt C, Corripio I, Dominguez E, Pomarol E, Salvador R, Pascual JC. Structural brain abnormalities in borderline personality disorder correlate with clinical severity and predict psychotherapy response. Brain Imaging and Behavior. 2021; 15(5). DOI:10.1007/s11682-021-00451-6. PMID:33634348. IF: 3,224
Sampedro F, Kulisevsky J. Intracortical surface-based MR diffusivity to investigate neurologic and psychiatric disorders: a review. JOURNAL OF NEUROIMAGING. 2022; 32(1). DOI:10.1111/jon.12930. PMID:34506674. IF: 3,870
Sampedro F, Marin J, Martinez S, Camacho V, Lopez DA, Pagonabarraga J, Kulisevsky J. Extrastriatal SPECT-DAT uptake correlates with clinical and biological features of de novo Parkinson’s disease. NEUROBIOLOGY OF AGING. 2021; 97. DOI:10.1016/j.neurobiolaging.2020.10.016. PMID:33212336. IF: 5,133
Sampedro F, Martinez S, Perez J, Perez R, Horta A, Campolongo A, Aracil I, Gomez B, Kulisevsky J. Interaction between sex and neurofilament light chain on brain structure and clinical severity in Huntington’s disease. Annals of Clinical and Translational Neurology. 2021; 8(12). DOI:10.1002/acn3.51460. PMID:34761569. IF: 5,430
Sampedro F, Perez J, Martinez S, Perez R, Horta A, Campolongo A, Izquierdo C, Pagonabarraga J, Gomez B, Kulisevsky J. Cortical microstructural correlates of plasma neurofilament light chain in Huntington’s disease. PARKINSONISM & RELATED DISORDERS. 2021; 85. DOI:10.1016/j.parkreldis.2021.03.008. PMID:33770670. IF: 4,402
Sampedro F, Roldan A, Alonso A, Grasa E, Portella MJ, Aguilar EJ, Nunez F, Gomez B, Corripio I. Grey matter microstructural alterations in schizophrenia patients with treatment-resistant auditory verbal hallucinations. JOURNAL OF PSYCHIATRIC RESEARCH. 2021; 138. DOI:10.1016/j.jpsychires.2021.03.037. PMID:33852993. IF: 5,250
Santos D, Fonticoba TD, Bartolome CC, Castro ES, Jesus S, Mir P, Pascual B, Pagonabarraga J, Kulisevsky J, Hernandez J, Planellas LL, Cabo I, Seijo M, Legarda I, Padilla FC, Caballol N, Cubo E, Nogueira V, Losada M, Ariztegui NL, Aramburu IG, Caldentey JG, Borrue C, Valero C, Alonso PS. Depression is Associated with Impulse-compulsive Behaviors in Parkinson’s disease. JOURNAL OF AFFECTIVE DISORDERS. 2021; 280. DOI:10.1016/j.jad.2020.11.075. PMID:33242731. IF: 6,533
Santos-Garcia D, Blazquez M, Calopa M, Escamilla F, Freire E, Ruiz PJG, Grandas F, Kulisevsky J, Lopez L, Castrillo JCM, Mir P, Pagonabarraga J, Perez F, Salom JM, Tijero B, Valldeoriola F, Yanez R, Aviles A, Luquin MR. Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project. Brain Sciences. 2021; 11(8):1027. DOI:10.3390/brainsci11081027. PMID:34439646. IF: 3,333
Santos-García D, Castro ES, de Deus Fonticoba T, Panceiras MJF, Enriquez JGM, González JMP, Bartolomé CC, Planellas LL, Caldentey JG, Caballol N, Legarda I, López IC, Manzanares LL, Rivera MAÁ, Catalán MJ, Nogueira V, Borrué C, Sauco MÁ, Vela L, Cubo E, Castrillo JCM, Alonso PS, Losada MGA, Ariztegui NL, Gastón MI, Kulisevsky J, Pagonabarraga J, et al. Sleep Problems Are Related to a Worse Quality of Life and a Greater Non-Motor Symptoms Burden in Parkinson’s Disease. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY. 2021;34(6):642-658. DOI:10.1177/0891988720964250. PMID: 33043810. IF: 2,718
Santos-García D, De Deus FT, Cores BC, Valdés AL, Suárez CE, Aneiros Á, Jesús S, Aguilar M, Pastor P, Planellas L, Cosgaya M, García CJ, Caballol N, Legarda I, Hernández VJ, Cabo I, López ML, González AI, Ávila RMA, José CM, Nogueira V, Puente V, García MJM, Borrué C, Solano VB, Álvarez SM, Vela L, Escalante S, Cubo E, Carrillo PF, Martínez CJC, et al.; COPPADIS Study Group [Kulisevsky J]. Mood in Parkinson’s disease: From early- to late-stage disease. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2021;36(5):627-646. DOI:10.1002/gps.5461. PMID: 33169885. IF: 3,850
Santos-Garcia D, Fonticoba TD, Cores C, Munoz G, Gonzalez JMP, Miro CM, Suarez E, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Vara JH, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Catalan MJ, Nogueira V, Puente V, de Arcos MR, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, Padilla FC, et al. [Kulisevsky J]. Predictors of clinically significant quality of life impairment in Parkinson’s disease. NPJ Parkinsons Disease. 2021; 7(1):118. DOI:10.1038/s41531-021-00256-w. PMID:34916528. IF: 9,304
Santos-Garcia D, Fonticoba TDD, Gonzalez JMP, Bartolome CC, Aymerich LV, Enriquez JGM, Suarez E, Jesus S, Aguilar M, Pastor P, Planellas LL, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Vara JH, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Catalan MJ, Nogueira V, Puente V, Moreno JMG, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, et al.; COPPADIS GRP [Kulisevsky J. Staging Parkinson’s Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life. Parkinsons Disease. 2021; 2021. DOI:10.1155/2021/8871549. PMID:34094501. IF: 3,170
Santos-Garcia D, Rios LN, Fonticoba TD, Bartolome CC, Roca LG, Painceiras MF, Miro CM, Canfield H, Jesus S, Aguilar M, Pastor P, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Vara JH, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Mayordomo VG, Nogueira V, Puente V, Dotor J, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, Padilla FC, et al. [Kulisevsky J]. Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Diagnostics. 2021; 11(12):2380. DOI:10.3390/diagnostics11122380. PMID:34943619. IF: 3,992
Santos-García D, de Deus T, Cores C, Canfield H, Paz González JM, Martínez Miró C, Valdés Aymerich L, Suárez E, Jesús S, Aguilar M, Pastor P, Planellas L, Cosgaya M, García Caldentey J, Caballol N, Legarda I, Hernández-Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Catalán MJ, Nogueira V, Puente V, Dotor J, Borrué C, et al.; Coppadis Study Group [Kulisevsky J]. Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson’s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine. 2021; 11(7):626. DOI:10.3390/jpm11070626. PMID:34209166. IF: 3,508
Stantonyonge N, Martinez S, Sampedro F, Sanchez MB, Chico A. Defective involuntary attention to novelty in type 1 diabetes and impaired awareness of hypoglycaemia. DIABETES RESEARCH AND CLINICAL PRACTICE. 2021; 177:108898. DOI:10.1016/j.diabres.2021.108898. PMID:34098058. IF: 8,180
Stantonyonge N, Sampedro F, Mendez J, Martinez S, Chico A, Gomez B. Structural Gray and White Matter Differences in Patients With Type 1 Diabetes and Impaired Awareness of Hypoglycemia. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2021; 106(2). DOI:10.1210/clinem/dgaa832. PMID:33180907. IF: 6,134
Storm CS, Kia DA, Almramhi MM, Bandres S, Finan C, Hingorani AD, Wood NW, Clarimón J, Dols O, Kulisevsky J, Marín J, Pagonabarraga J, Lynch TL. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome. Nature Communications. 2021; 12(1):7342. DOI:10.1038/s41467-021-26280-1. PMID:34930919. IF: 17,694

2017 Scientific Report – Parkinson Diseases and Movement disorders

Introduction

Main lines of research

Cognitive Impairment and Behavioural Dysfunctions in Parkinson Disease

Knowledge and detection of the neural correlates of cognitive performance in Parkinson disease using neurophysiological techniques (event-related brain cognitive potentials) and structural and functional neuroimaging (voxel-based morphometry, cortical thickness and spectroscopy).
Development of more sensitive tools for cognitive and functional assessment in Parkinson disease to detect subtle changes in cognitive performance and treatment response.
Prospective follow-up analysis of cognition and mood in patients with deep-brain stimulation of the subthalamic nucleus.
Physiological correlates and pharmacological approach to apathy in Parkinson disease and other movement disorders.
Neurophysiological and cognitive correlates of impulse control disorders in Parkinson disease and other movement disorders. Behavioral and pharmacological treatment.
Surgery and treatments of continuous infusion in Parkinson disease.
Follow-up and etiologic study of weight loss in patients treated with continuous infusion of intraduodenal levodopa.
Follow-up and etiologic study of weight loss in patients treated with continuous infusion of intraduodenal levodopa.

Essential Tremor and Other Movement Disorders

Molecular neuroimaging in essential tremor.
Clinical, neurophysiological and neuroimaging assessment of patients with FXTAS (fragile X-associated tremor/ataxia syndrome).

Translational Research – Parkinsonian Animal Models

Assessment of behavioural and cognitive modulations exerted by distinct antiparkinsonian drugs in murine models of Parkinson disease with lesions in particular neurotransmitter systems (dopaminergic and noradrenergic lesions).
Assessment of behavioural and cognitive traits of murine models of HD

Translational Research – Cell Models

Assessment of cell cultures of neurons derived of induced pluripotent cells (iPSCs) obtained from skin fibroblast as in vitro model for the modulation of key factors associated to both cognitive and neurotransmitter disturbances in Parkinson disease.

Huntington Disease

Study of the metabolic correlates (18-FDG PET) of disease progression from the pre-manifested to early-stages.
Study of the metabolic correlates (18-FDG PET) of apathy and depression in pre-manifested gene carriers.
Functional magnetic resonance imaging study of reward sensitivity in pre-manifested an early-stage Huntington’s disease.
Determination of the prevalence and clinical significance of neuropsychiatric features in Huntington’s disease.
Development of new instruments for cognitive and functional assessment in Huntington’s disease.
Prospective observational study of Huntington’s disease in a European cohort (Registry Study).
Molecular, clinical, behavioural and cognitive characterisation of the BACHD rat model of Huntington’s disease.
Collaboration in multicentre and Spanish coordinated projects:
- Relationship between intermediate alleles and clinical manifestations (PI: Esther Cubo, Burgos).
- Validation of the Spanish version of the Problem Behaviour Assessment Scale (PBA-S; PI: Jesús Ruiz, Barcelona).
- Study of dietary intake in Huntington’s disease (PI: Esther Cubo, Burgos).
- A multimodal neuroimaging approach to delineate emotional, motor and cognitive cortico-striatal pathways. IDIBELL (PI: Ruth de Diego-Balaguer, Barcelona).

Progresive Supranuclear Palsy

Development of a cognitive rating scale.
Development of a standarized eye movement evaluation.

Challenges

Cognitive and Behavioural Dysfunctions in Parkinson Disease

Study and understanding of the neural substrates of cognitive impairment in Parkinson disease so as to improve diagnostic and therapeutic approaches.
Development of specific tools to assess and track cognitive changes in Parkinson disease.

Huntington’s Disease

Study of the dynamics of mutant Htt protein aggregation and related neural and cognitive correlates along disease stages in Huntington’s disease.
Validation of new instruments to assess and track subtle cognitive changes in pre-manifested and early-stage Huntington’s disease population.

Essential Tremor and Other Movement Disorders

Genetic studies and genotype-phenotype correlations in essential tremor.
Development of new therapeutic interventions in essential tremor.
Neurochemical and structural neuroimaging studies on the pathophysiological bases of essential tremor.

Translational Research – Animal Models of Parkinsonism

Behavioural, physiological and pharmacological characterization of animal models of parkinsonism with combined dopaminergic and noradrenergic lesions.
Physiopathology of motor, cognitive and behavioural complications linked to antiparkinsonian drugs in animal models of parkinsonism.

Team

Group coordination

KULISEVSKY BOJARSKI, JAIME FGS
jkulisevsky@santpau.cat

Members

Scientific output

Publications 2022

(JIF 2022)

Abdelnour C, Ferreira D, van de Beek M, Cedres N, Oppedal K, Cavallin L, Blanc F, Bousiges O, Wahlund LO, Pilotto A, Padovani A, Boada M, Pagonabarraga J, Kulisevsky J, Aarsland D, Lemstra AW, Westman E. Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. Alzheimers Research & Therapy. 2022; 14(1):14. DOI:10.1186/s13195-021-00946-w. PMID:35063023. IF:9 (Q1/1D). Document type: Article.
Aracil I, Martinez S, Gonzalez JM, Sampedro F, Perez J, Horta A, Campolongo A, Izquierdo C, Gomez B, Pagonabarraga J, Kulisevsky J. Structure and Dynamics of Large-Scale Cognitive Networks in Huntington’s Disease. MOVEMENT DISORDERS. 2022; 37(2). DOI:10.1002/mds.28839. PMID:34752656. IF:8,6 (Q1/1D). Document type: Article.
Aracil I, Sampedro F, Marin J, Horta A, Martinez S, Gonzalez JM, Perez J, Bejr H, Pascual B, Boti M, Campolongo A, Izquierdo C, Gironell A, Gomez B, Kulisevsky J, Pagonabarraga J. Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson’s disease mild cognitive impairment. Brain Imaging and Behavior. 2022; 16(2). DOI:10.1007/s11682-021-00543-3. PMID:34553331. IF:3,2 (Q2/5D). Document type: Article.
Aretouli E, Chondrogiorgi M, Dede O, Koutsonida M, Lafi C, Konstantinopoulou E, Kulisevsky J, Kosmidis MH, Konitsiotis S. The Parkinson’s Disease-Cognitive Rating Scale: Greek Normative Data, Clinical Utility and Cultural Considerations. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY. 2022; 35(5):08919887211049110. DOI:10.1177/08919887211049110. PMID:34663111. IF:2,6 (Q3/7D). Document type: Article.
Asl AM, Mehdizadeh M, Kulisevsky J, Sabet A, Sharabiani P, Mehdizadeh H, Ashayeri H, Taghizadeh G. Reliability, validity, and diagnostic accuracy of Parkinson’s Disease-Cognitive Rating Scale in Iranian patients with idiopathic Parkinson’s disease. DISABILITY AND REHABILITATION. 2022; 44(10). DOI:10.1080/09638288.2020.1813337. PMID:32924645. IF:2,2 (Q2/4D). Document type: Article.
Bach L, Boccalatte F, DeRosa A, Devos D, Garcia C, Inglese M, Droby A. Functional changes in prefrontal cortex following frequency-specific training. Scientific Reports. 2022; 12(1):20316. DOI:10.1038/s41598-022-24088-7. PMID:36434008. IF:4,6 (Q2/3D). Document type: Article.
Bejr H, Martinez S, Pagonabarraga J, Marin J, Horta A, Sampedro F, Aracil I, Perez J, Campolongo A, Izquierdo C, Pascual B, Kulisevsky J. The role of attentional control over interference in minor hallucinations in Parkinson’s disease. PARKINSONISM & RELATED DISORDERS. 2022; 102. DOI:10.1016/j.parkreldis.2022.07.009. PMID:35987038. IF:4,1 (Q2/3D). Document type: Article.
Calabria M, Garcia C, Grunden N, Pons C, Arroyo JA, Gomez B, Garcia M, Belvis R, Morollon N, Igual JV, Mur I, Pomar V, Domingo P. Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms. JOURNAL OF NEUROLOGY. 2022; 269(8). DOI:10.1007/s00415-022-11141-8. PMID:35488918. IF:6 (Q1/2D). Document type: Article.
De la Riva P, Rodriguez J, Gomez V, Arenaza G, Gorostidi A, Diez N, De Arce A, Martinez M, Gonzalez F, Luttich A, Garmendia E, Sola A, Larrea JA, Bergareche A, Sobrino T. Endothelial NO synthase 786T/T polymorphism increases hemorrhagic transformation after endovascular thrombectomy. NITRIC OXIDE-BIOLOGY AND CHEMISTRY. 2022; 129. DOI:10.1016/j.niox.2022.08.006. PMID:36067953. IF:3,9 (Q2/5D). Document type: Article.
De Paepe AE, Garcia C, Martinez S, Perez JP, Kulisevsky J, Rodriguez N, Vaquer I, Subira S, Calopa M, Santacruz P, Munoz E, Mareca C, Ruiz J, De Diego R, Camara E. Delineating apathy profiles in Huntington’s disease with the short-Lille Apathy Rating Scale. PARKINSONISM & RELATED DISORDERS. 2022; 105. DOI:10.1016/j.parkreldis.2022.10.025. PMID:36395542. IF:4,1 (Q2/3D). Document type: Article.
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Delannoy PG, Poewe W, Compta Y, Pavese N, Ruzicka E, Dusek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory F, Walter U, de Bie R, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, et al. Trial of Deferiprone in Parkinson’s Disease. NEW ENGLAND JOURNAL OF MEDICINE. 2022; 387(22). DOI:10.1056/NEJMoa2209254. PMID:36449420. IF:158,5 (Q1/1D). Document type: Article.
Ferraro PM, Spotorno N, Finegan E, Sampedro F, Caso F. Editorial: Genotype-phenotype correlations in neurodegenerative diseases: From clinical features to neuroimaging signatures. Frontiers in Neurology. 2022; 13:1100953. DOI:10.3389/fneur.2022.1100953. PMID:36588898. IF:3,4 (Q2/5D). Document type: Editorial material.
Ferreira JJ, Rodrigues FB, Duarte GS, Mestre TA, Bachoud AC, Bentivoglio AR, Burgunder JM, Cardoso F, Claassen DO, Landwehrmeyer GB, Kulisevsky J, Nirenberg MJ, Rosser A, Roth J, Seppi K, Slawek J, Furr E, Tabrizi SJ, Walker FO, Vandenberghe W, Costa J, Sampaio C. An MDS Evidence-Based Review on Treatments for Huntington’s Disease. MOVEMENT DISORDERS. 2022; 37(1). DOI:10.1002/mds.28855. PMID:34842303. IF:8,6 (Q1/1D). Document type: Review.
Garcia C, Calabria M, Grunden N, Pons C, Arroyo JA, Gomez B, Lleo A, Alcolea D, Belvis R, Morollon N, Mur I, Pomar V, Domingo P. Neuropsychological deficits in patients with cognitive complaints after COVID-19. Brain and Behavior. 2022; 12(3):e2508. DOI:10.1002/brb3.2508. PMID:35137561. IF:3,1 (Q2/3D). Document type: Article.
Garcia DS, Roca LG, Fonticoba TD, Bartolome CC, Rios LN, Canfield H, Gonzalez JMP, Miro CM, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Vara JH, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Mayordomo VG, Nogueira V, Puente V, Garcia JD, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, Padilla FC, et al. [Kulisevsky J]. Constipation Predicts Cognitive Decline in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. Journal of Parkinsons Disease. 2022; 12(1). DOI:10.3233/JPD-212868. PMID:34602501. IF:5,2 (Q1/3D). Document type: Article.
Garcia DS, Sauco MA, Calopa M, Carrillo F, Sevilla FE, Freire E, Ramos RG, Kulisevsky J, Esteban JCG, Legarda I, Luquin M, Castrillo JCM, Martinez P, Martinez I, Mir P, Ignacio AS. MNCD: A New Tool for Classifying Parkinson’s Disease in Daily Clinical Practice. 2022; 12(1):55. DOI:10.3390/diagnostics12010055. PMID:35054222. IF:3,6 (Q2/4D). Document type: Article.
Horta A, Martinez S, Perez J, Sampedro F, Puig A, Pagonabarraga J, Kulisevsky J. Measuring the functional impact of cognitive impairment in Huntington’s disease. JOURNAL OF NEUROLOGY. 2022; 269(7). DOI:10.1007/s00415-021-10955-2. PMID:35061089. IF:6 (Q1/2D). Document type: Article.
Illan I, Nigro S, VandeVrede L, Falgas N, Heuer HW, Painous C, Compta Y, Marti MJ, Montal V, Pagonabarraga J, Kulisevsky J, Lleo A, Fortea J, Logroscino G, Quattrone A, Quattrone A, Perry DC, Gorno ML, Rosen HJ, Grinberg LT, Spina S, La Joie R, Rabinovici GD, Miller BL, Rojas JC, Seeley WW, Boxer AL. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open. 2022; 5(4):e229588. DOI:10.1001/jamanetworkopen.2022.9588. PMID:35486397. IF:13,8 (Q1/1D). Document type: Article.
Kulisevsky J, Martinez S, Campolongo A, Pascual B, Marin J, Bejr H, Aracil I, Horta A, Puig A, Pagonabarraga J. A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson’s Disease. Frontiers in Neurology. 2022; 13:866502. DOI:10.3389/fneur.2022.866502. PMID:35720066. IF:3,4 (Q2/5D). Document type: Article.
Kulisevsky J. Pharmacological management of Parkinson’s disease motor symptoms: update and recommendations from an expert. REVISTA DE NEUROLOGIA. 2022; 75(s04):S1-S10. DOI:10.33588/rn.75s04.2022217. PMID:36342310. IF:1,2 (Q4/10D). Document type: Review.
Marin J, Martinez S, Pagonabarraga J, Horta A, Aracil I, Bejr H, Sampedro F, Campolongo A, Kulisevsky J. Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers. ANNALS OF NEUROLOGY. 2022; 92(6). DOI:10.1002/ana.26486. PMID:36054656. IF:11,2 (Q1/1D). Document type: Article.
Mauricio D, Vlacho B, de la Puente JB, Mundet X, Real J, Kulisevsky J, Ortega E, Castelblanco E, Julve J, Franch J. Associations Between Diabetic Retinopathy and Parkinson’s Disease: Results From the Catalonian Primary Care Cohort Study. Frontiers in Medicine. 2022; 8:800973. DOI:10.3389/fmed.2021.800973. PMID:35118094. IF:8,1 (Q1/2D). Document type: Article.
Pagonabarraga J, Perez R, Bejr H, Marin J, Horta A, Martinez S, Aracil I, Sampedro F, Campolongo A, Rivas E, Puig A, Ruiz I, Perez J, Pascual B, Kulisevsky J. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson’s disease. PARKINSONISM & RELATED DISORDERS. 2022; 105. DOI:10.1016/j.parkreldis.2022.05.020. PMID:35752549. IF:4,1 (Q2/3D). Document type: Article.
Pérez C, Hernández J, Caballol N, Bayes À, Buongiorno M, Lopez N, Gironell A, López J, Martínez JC, Sauco A, López L, Escalante S, Pérez DA, Rodríguez A, The MoMoPa G. Comparison of the Results of a Parkinson’s Holter Monitor With Patient Diaries, in Real Conditions of Use: A Sub-analysis of the MoMoPa-EC Clinical Trial. Frontiers in Neurology. 2022; 13:835249. DOI:10.3389/fneur.2022.835249. PMID:35651347. IF:3,4 (Q2/5D). Document type: Article.
Pou MA, Orfila F, Pagonabarraga J, Ferrer S, Corominas H, Diaz C. Le risque de maladie de Parkinson dans une population méditerranéenne de patients goutteux : étude cas-témoins. Revue Du Rhumatisme (edition Francaise). 2022; 89(6). DOI:10.1016/j.rhum.2022.09.019. Document type: Article.
Pou MA, Orfila F, Pagonabarraga J, Ferrer S, Corominas H, Diaz C. Risk of Parkinson’s disease in a gout Mediterranean population: A case-control study. JOINT BONE SPINE. 2022; 89(6):105402. DOI:10.1016/j.jbspin.2022.105402. PMID:35504516. IF:4,2 (Q2/4D). Document type: Article.
Rodríguez F, Beltrán Á, Chico JL, Parra P, Baena B, Pagonabarraga J, Pérez P, Pareés I, López JL, Martínez JC, Alonso A. Efficacy and safety of high doses of safinamide in advanced Parkinson disease. PARKINSONISM & RELATED DISORDERS. 2022; 97. DOI:10.1016/j.parkreldis.2022.03.010. PMID:35344893. IF:4,1 (Q2/3D). Document type: Letter.
Rosas I, Morís G, Coto E, Blázquez M, Suárez E, García C, Martínez C, Herrera ID, Pérez S, Álvarez V, Menéndez M, Adarmes AD, Aguilar M, Alvarez I, Barrero FJ, Bergareche JA, Bonilla M, Botía JA, Boungiorno MT, Buiza D, Cámara A, Carrillo F, Cerdan D, Clarimón J, Compta Y, Diez M, Dols-Icardo O, de Fabregues O, Cartagena PS, Duarte J, Duran R, Escamilla F, et al. [Kulisevsky J, Pagonabarraga J, Pascual Sedano B, ]. Smoking is associated with age at disease onset in Parkinson’s disease. PARKINSONISM & RELATED DISORDERS. 2022; 97. DOI:10.1016/j.parkreldis.2022.03.005. PMID:35364453. IF:4,1 (Q2/3D). Document type: Article.
Ruiz I, Horta A, Illan I, Kulisevsky J, Pagonabarraga J. Genotype-Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities. Frontiers in Neurology. 2022; 13:861585. DOI:10.3389/fneur.2022.861585. PMID:35557621. IF:3,4 (Q2/5D). Document type: Review.
Saiz M, Gil C, Diez M, Martinez SI, Santalo FS, Calvo S, Alonso E, Rinones E, Aguado L, Mariscal N, Munoz I, Pineiro D, Rivadeneyra J, Cubo E. Polymorphisms in the oxytocin receptor and their association with apathy and impaired social cognition in Huntington’s disease. NEUROLOGICAL SCIENCES. 2022; 43(10). DOI:10.1007/s10072-022-06226-1. PMID:35725858. IF:3,3 (Q2/5D). Document type: Article.
Sampedro F, Aracil I, Farres C, Soler J, Schmidt C, Elices M, Pomarol E, Salvador R, Vega D, Pascual JC. A Functional Connectivity Study to Investigate the Role of the Right Anterior Insula in Modulating Emotional Dysfunction in Borderline Personality Disorder. PSYCHOSOMATIC MEDICINE. 2022; 84(1). DOI:10.1097/PSY.0000000000001019. PMID:34611112. IF:3,3 (Q2/4D). Document type: Article.
Sampedro F, Camara E, Kulisevsky J. Editorial: Neuroimaging of Cognitive and Neuropsychiatric Symptoms in Movement Disorders. Frontiers in Neurology. 2022; 13:843440. DOI:10.3389/fneur.2022.843440. PMID:35173676. IF:3,4 (Q2/5D). Document type: Editorial material.
Sampedro F, Kulisevsky J. Intracortical surface-based MR diffusivity to investigate neurologic and psychiatric disorders: a review. JOURNAL OF NEUROIMAGING. 2022; 32(1). DOI:10.1111/jon.12930. PMID:34506674. IF:2,4 (Q3/6D). Document type: Review.
Sampedro F, Martinez S, Horta A, Grothe MJ, Labrador MA, Jesus S, Adarmes A, Carrillo F, Puig A, Lora FR, Barbera MA, Pastor P, Arroyo SE, Vila BS, Foraster AC, Martinez JR, Padilla FC, Morlans MP, Aramburu IG, Ceberio JI, Vara JH, de Fabregues O, de Deus T, Avila A, Martinez JC, Bejr H, Campolongo A, Pascual B, Martinez P, Santos D, Mir P, Kulisevsky J. Increased homocysteine levels correlate with cortical structural damage in Parkinson’s disease. JOURNAL OF THE NEUROLOGICAL SCIENCES. 2022; 434:120148. DOI:10.1016/j.jns.2022.120148. PMID:35085959. IF:4,4 (Q2/3D). Document type: Article.
Sampedro F, Martinez S, Horta A, Grothe MJ, Labrador MA, Jesus S, Adarmes A, Carrillo F, Puig A, Roldan F, Aguilar M, Pastor P, Arroyo SE, Vila BS, Cots A, Ruiz J, Carrillo F, Pueyo M, Gonzalez I, Infante J, Hernandez J, de Fabregues O, Fonticoba TD, Avila A, Martinez JC, Bejr H, Campolongo A, Pascual B, Martinez P, Santos D, Mir P, Garcia PJ, Kulisevsky J. Clinical and structural brain correlates of hypomimia in early-stage Parkinson’s disease. EUROPEAN JOURNAL OF NEUROLOGY. 2022; 29(12). DOI:10.1111/ene.15513. PMID:35852918. IF:5,1 (Q1/2D). Document type: Article.
Sampedro F, Martínez S, Kulisevsky J. Response to letter: “Association of elevated blood homocysteine with cognitive decline in early, untreated Parkinson’s disease”. JOURNAL OF THE NEUROLOGICAL SCIENCES. 2022; 438:120272. DOI:10.1016/j.jns.2022.120272. PMID:35576640. IF:4,4 (Q2/3D). Document type: Letter.
Sampedro F, Martinez S, Marin J, Pagonabarraga J, Kulisevsky J. Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson’s Disease. Journal of Parkinsons Disease. 2022; 12(5). DOI:10.3233/JPD-223223. PMID:35491803. IF:5,2 (Q1/3D). Document type: Article.
Sampedro F, Martinez S, Perez J, Perez R, Horta A, Campolongo A, Izquierdo C, Aracil I, Rivas E, Puig A, Pagonabarraga J, Gomez B, Kulisevsky J. Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntington’s Disease. Clinical Neuroradiology. 2022; 32(4). DOI:10.1007/s00062-022-01150-5. PMID:35238950. IF:2,8 (Q2/5D). Document type: Article.
Santos D, Canfield H, de Deus T, Cores C, Naya L, García L, Martínez C, Jesús S, Aguilar M, Pastor P, Cosgaya M, García J, Caballol N, Legarda I, Hernández J, Cabo I, López L, González I, Ávila MA, Gómez V, Nogueira V, Puente V, Dotor J, Borrué C, Solano B, Álvarez M, Vela L, Escalante S, Cubo E, Carrillo F, Martínez JC, Sánchez P, Alonso MG, López N, Gastón I, Kulisevsky J, et al. Parkinson’s Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Parkinsons Disease. 2022; 12(3). DOI:10.3233/JPD-213004. PMID:34957949. IF:5,2 (Q1/3D). Document type: Article.
Santos D, Fonticoba TD, Bartolome CC, Alvarado M, Panceiras MJF, Castro ES, Canfield H, Miro CM, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Vara JH, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Mayordomo VG, Nogueira V, Puente V, Garcia JD, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, et al. [Kulisevsky J]. Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson’s disease patients. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2022; 37(6):GPS5761. DOI:10.1002/gps.5761. PMID:35633051. IF:4 (Q2/5D). Document type: Article.
Santos D, Fonticoba TD, Bartolome CC, Painceiras MJF, Castro ES, Canfield H, Miro CM, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Hernandez J, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Mayordomo VG, Nogueira V, Puente V, Garcia JD, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, Padilla FC, et al. [Kulisevsky J]. Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson’s Disease Patients: A 2-Year Follow-Up Study. 2022; 12(5):1147. DOI:10.3390/diagnostics12051147. PMID:35626303. IF:3,6 (Q2/4D). Document type: Article.
Stocchi F, Antonini A, Berg D, Bergmans B, Jost W, Katzenschlager R, Kulisevsky J, Odin P, Valldeoriola F, Chaudhuri KR. Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus. npj Parkinsons Disease. 2022; 8(1):17. DOI:10.1038/s41531-022-00277-z. PMID:35190544. IF:8,7 (Q1/1D). Document type: Article.
Valle N, Pérez R, Chiva G, Belbin O, Serrano S, Sirisi S, González AC, Giró O, Sánchez É, Dols O, Alcolea D, Carmona M, Jimenez A, Lleó A, Fortea J, Iulita MF. Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma. Jove-Journal of Visualized Experiments. 2022; 2022(186):e64107. DOI:10.3791/64107. PMID:35993755. IF:1,2 (Q3/8D). Document type: Article.

Publications 2021

Abbruzzese G, Kulisevsky J, Bergmans B, Gomez JC, Kagi G, Raw J, Stefani A, Warnecke T, Jost WH, SYNAPSES Study Investigators GRP. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. Journal of Parkinsons Disease. 2021; 11(1). DOI:10.3233/JPD-202224. PMID:33104040. IF: 5,520
Aracil I, Sampedro F, Pujol J, Soriano C, Gonzalez JM, Kulisevsky J, Pagonabarraga J. The impact of dopaminergic treatment over cognitive networks in Parkinson’s disease: Stemming the tide?. HUMAN BRAIN MAPPING. 2021; 42(17). DOI:10.1002/hbm.25650. PMID:34510640. IF: 5,399
Bejr-Kasem H, Sampedro F, Marín-Lahoz J, Martínez-Horta S, Pagonabarraga J, Kulisevsky J. Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson’s disease. European Journal of Neurology. 2021;28(2):438-447. DOI:10.1111/ene.14576. PMID: 33032389. IF: 6,288
Bernasconi F, Blondiaux E, Potheegadoo J, Stripeikyte G, Pagonabarraga J, Bejr H, Bassolino M, Akselrod M, Martinez S, Sampedro F, Hara M, Horvath J, Franza M, Konik S, Bereau M, Ghika JA, Burkhard PR, Van de Ville D, Faivre N, Rognini G, Krack P, Kulisevsky J, Blanke O. Robot-induced hallucinations in Parkinson’s disease depend on altered sensorimotor processing in fronto-temporal network. Science Translational Medicine. 2021; 13(591):eabc8362. DOI:10.1126/scitranslmed.abc8362. PMID:33910980. IF: 19,319
Blauwendraat C, Iwaki H, Makarious MB, Bandres S, Leonard HL, Grenn FP, Lake J, Krohn L, Tan M, Kim JJ, Gibbs JR, Hernandez DG, Ruskey JA, Pihlstrom L, Toft M, van JJ, Marinus J, Schulte C, Brockmann K, Sharma M, Siitonen A, Majamaa K, Eerola J, Tienari PJ, Grosset DG, Lesage S, Corvol JC, Brice A, Wood N, et al. [Clarimón J, Dols O, Kulisevsky J, Pagonabarraga J]. Investigation of Autosomal Genetic Sex Differences in Parkinson’s Disease. ANNALS OF NEUROLOGY. 2021; 90(1). DOI:10.1002/ana.26090. PMID:33901317. IF: 11,274
Calabria M, Perez JP, Martinez S, Horta A, Carceller M, Kulisevsky J, Costa A. Language reconfiguration in bilinguals A study with Huntington’s disease patients. Linguistic Approaches to Bilingualism. 2021; 11(4). DOI:10.1075/lab.18022.cal. IF: 1,815
Chen ZB, Zhang D, Reynolds RH, Gustavsson EK, Garcia S, D’Sa K, Fairbrother A, Vandrovcova J, Hardy J, Houlden H, Taliun S, Botia J, Ryten M, Clarimón J, Dols O, Kulisevsky J, Pagonabarraga J, Int Parkinson’s Dis Genomics C. Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage. Nature Communications. 2021; 12(1):2076. DOI:10.1038/s41467-021-22262-5. PMID:33824317. IF: 17,694
De Paepe AE, Ara A, Garcia C, Martinez S, Perez J, Kulisevsky J, Rodriguez N, Vaquer I, Subira S, Calopa M, Munoz E, Santacruz P, Ruiz J, Mareca C, de Diego R, Camara E. Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington’s Disease. MOVEMENT DISORDERS. 2021; 36(9). DOI:10.1002/mds.28638. PMID:33998063. IF: 9,698
Diez M, Houle G, Ortega S, Bandres S, Alvarez I, Carcel M, Ibanez L, Fernandez MV, Budde JP, Trotta JR, Tonda R, Chong JX, Bamshad MJ, Nickerson DA, Aguilar M, Tartari JP, Gironell A, Garcia E, Agundez J, Alonso H, Jimenez FJ, Fernandez M, Valldeoriola F, Marti MJ, Tolosa E, Coria F, Pastor MA, Vilarino C, Rajput A, Dion PA, Cruchaga C, Rouleau GA, Pastor P, U. Exome-wide rare variant analysis in familial essential tremor. PARKINSONISM & RELATED DISORDERS. 2021; 82. DOI:10.1016/j.parkreldis.2020.11.021. PMID:33279834. IF: 4,402
Gaig C, Compta Y, Heidbreder A, Marti MJ, Titulaer MJ, Crijnen Y, Hogl B, Lewerenz J, Erro ME, Garcia JC, Nigro P, Tambasco N, Patalong M, Erdler M, Macher S, Berger E, Hoftberger R, Geis C, Hutterer M, Milan A, Martin A, Manzanares LL, Quintas S, Hoglinger GU, Mohn N, Schoberl F, Thaler FS, Asioli GM, Provini F, Plazzi G, Berganzo K, Blaabjerg M, et al. [Perez JP]. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. NEUROLOGY. 2021; 97(14). DOI:10.1212/WNL.0000000000012639. PMID:34380749. IF: 11,800
Garcia R, Santos D, Alonso A, Alvarez M, Ares B, Avila A, Caballol N, Carrillo F, Sevilla FE, Freire E, Esteban JCG, Legarda I, Manzanares LL, Valdes EL, Martinez I, Mata M, Parees I, Pascual B, Mir P, Castrillo JCM. Management of Parkinson’s disease and other movement disorders in woman of childbearing age: Part 1. NEUROLOGIA. 2021; 36(2). DOI:10.1016/j.nrl.2020.05.010. PMID:32718872. IF: 5,486
Garcia R, Santos D, Alonso A, Alvarez M, Ares B, Avila A, Caballol N, Carrillo F, Sevilla FE, Freire E, Esteban JCG, Legarda I, Manzanares LL, Valdes EL, Martinez I, Mata M, Parees I, Pascual B, Castrillo JCM, Mir P. Management of Parkinson’s disease and other movement disorders in women of childbearing age: Part 2. NEUROLOGIA. 2021; 36(2). DOI:10.1016/j.nrl.2020.05.012. PMID:32980194. IF: 5,486
Gialluisi A, Reccia MG, Modugno N, Nutile T, Lombardi A, Di LG, Pietracupa S, Ruggiero D, Scala S, Gambardella S, Iacoviello L, Gianfrancesco F, Acampora D, D’Esposito M, Simeone A, Ciullo M, Esposito T, Kulisevsky J, Pagonabarraga J, Int Parkinsons Dis Genomics C. Identification of sixteen novel candidate genes for late onset Parkinson’s disease. Molecular Neurodegeneration. 2021; 16(1):35. DOI:10.1186/s13024-021-00455-2. PMID:34148545. IF: 18,879
Grothe MJ, Labrador MA, Jesus S, Macias D, Adarmes A, Carrillo F, Camacho EI, Franco P, Lora FR, Martin JF, Barbera MA, Pastor P, Arroyo SE, Vila BS, Foraster AC, Martinez JR, Padilla FC, Morlans MP, Aramburu IG, Ceberio JI, Vara JH, de Fabregues O, Fonticoba TD, Pascual B, Kulisevsky J, Martinez P, Santos D, Mir P. In vivo cholinergic basal forebrain degeneration and cognition in Parkinson’s disease: Imaging results from the COPPADIS study. PARKINSONISM & RELATED DISORDERS. 2021; 88. DOI:10.1016/j.parkreldis.2021.05.027. PMID:34144230. IF: 4,402
Horta A, Pagonabarraga J, Martinez S, Busteed L, Pascual B, Illan I, Marin J, Aracil I, Perez J, Sampedro F, Bejr H, Kulisevsky J. Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. JOURNAL OF NEUROLOGY. 2021; 268(9). DOI:10.1007/s00415-021-10511-y. PMID:33704556. IF: 6,682
Jost ST, Visser V, Rizos A, Loehrer PA, Silverdale M, Evans J, Samuel M, Petry JN, Sauerbier A, Gronostay A, Barbe MT, Fink GR, Ashkan K, Antonini A, Martinez P, Chaudhuri KR, Timmermann L, Dafsari HS, Pagonabarraga J, Walker RW. Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. npj Parkinsons Disease. 2021; 7(1):48. DOI:10.1038/s41531-021-00174-x. PMID:34103534. IF: 9,304
Kia DA, Zhang D, Guelfi S, Manzoni C, Hubbard L, Reynolds RH, Botia J, Ryten M, Ferrari R, Lewis PA, Williams N, Trabzuni D, Hardy J, Wood NW, Clarimón J, Dols O, Kulisevsky J, Pagonabarraga J, United B, Int Parkinsons Dis G. Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurology. 2021; 78(4). DOI:10.1001/jamaneurol.2020.5257. PMID:33523105. IF: 29,907
Lage C, Lopez S, Bejanin A, Kazimierczak M, Aracil I, Calvo A, Pozueta A, Garcia M, Fernandez A, Bravo M, Jimenez J, Banzo I, Irure J, Pegueroles J, Illan I, Fortea J, Rodriguez E, Lleo A, Garcia CE, Sanchez P. Distinctive Oculomotor Behaviors in Alzheimer’s Disease and Frontotemporal Dementia. Frontiers in Aging Neuroscience. 2021; 12:603790. DOI:10.3389/fnagi.2020.603790. PMID:33613262. IF: 5,702
Leon P, Pagonabarraga J, Moris J, Martinez S, Marin J, Horta A, Bejr H, Kulisevsky J, Rodriguez A. Neural signatures of predictive language processing in Parkinson’s disease with and without mild cognitive impairment. CORTEX. 2021; 141. DOI:10.1016/j.cortex.2021.03.032. PMID:34049254. IF: 4,644
Martinez S, Bejr H, Horta A, Pascual B, Santos D, De Deus T, Jesus S, Aguilar M, Planellas L, Garcia J, Caballol N, Vives B, Hernandez J, Cabo I, Lopez L, Gonzalez I, Avila MA, Catalan MJ, Lopez LM, Puente V, Garcia JM, Borrue C, Solano B, Alvarez M, Vela L, Escalante S, Cubo E, Carrillo F, Martinez JC, Sanchez P, Alonso MG, Lopez N, Gaston I, et al. [Kulisevsky J]. Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson’s disease. BMC Neurology. 2021; 21(1):477. DOI:10.1186/s12883-021-02485-1. PMID:34879838. IF: 2,903
Martinez S, Ivanir E, Perrinjaquet T, Keuter MH, Kulisevsky J. Effects of a Green Oat Herb Extract on Cognitive Performance and Neurophysiological Activity: A Randomized Double-Blind Placebo-Controlled Study. Frontiers in Neuroscience. 2021; 15:748188. DOI:10.3389/fnins.2021.748188. PMID:34658781. IF: 5,152
Martinez-Horta S, Sampedro F, Horta-Barba A, Perez-Perez J, Pagonabarraga J, Gomez-Anson B, Kulisevsky J. Structural brain correlates of irritability and aggression in early manifest Huntington’s disease. Brain Imaging and Behavior. 2021;15(1):107-113. DOI:10.1007/s11682-019-00237-x. PMID: 31898092. IF: 3,224
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A, PASADENA I, Bejr H, Bojarsky JK, Prasinezumab GRP. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson’s Disease (PASADENA): Rationale, Design, and Baseline Data. Frontiers in Neurology. 2021; 12:705407. DOI:10.3389/fneur.2021.705407. PMID:34659081. IF: 4,086
Pagonabarraga J, Horta A, Busteed L, Bejr H, Illan I, Aracil I, Marin J, Pascual B, Perez J, Campolongo A, Izquierdo C, Martinez S, Sampedro F, Kulisevsky J. Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy. PARKINSONISM & RELATED DISORDERS. 2021; 85. DOI:10.1016/j.parkreldis.2021.03.002. PMID:33744691. IF: 4,402
Pagonabarraga J, Tinazzi M, Caccia C, Jost WH. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson’s disease: Clinical cases and a review of the literature. JOURNAL OF CLINICAL NEUROSCIENCE. 2021; 90. DOI:10.1016/j.jocn.2021.05.056. PMID:34275546. IF: 2,116
Perez A, Giraldo DM, Rios J, Munoz E, Compta Y, Marti MJ, Pagonabarraga J. Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry. Journal of Parkinsons Disease. 2021; 11(2). DOI:10.3233/JPD-202332. PMID:33492245. IF: 5,520
Pezzoli S, Sanchez R, Solanes A, Kempton MJ, Bandmann O, Il J, Cagnin A, Goldman JG, Merkitch D, Firbank MJ, Taylor JP, Pagonabarraga J, Kulisevsky J, Blanc F, Verdolini N, Venneri A, Radua J. Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson’s disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS. 2021; 128. DOI:10.1016/j.neubiorev.2021.06.030. PMID:34171324. IF: 9,052
Rodriguez A, Hernandez J, Minarro A, Perez C, Bayes A, Martinez JC, Perez DA, Gironell A, Monitoring Parkinsons Patients M. Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson’s symptoms against other clinical monitoring methods: study protocol. BMJ Open. 2021; 11(7):e045272. DOI:10.1136/bmjopen-2020-045272. PMID:34281918. IF: 3,006
Sampedro F, Farres C, Soler J, Elices M, Schmidt C, Corripio I, Dominguez E, Pomarol E, Salvador R, Pascual JC. Structural brain abnormalities in borderline personality disorder correlate with clinical severity and predict psychotherapy response. Brain Imaging and Behavior. 2021; 15(5). DOI:10.1007/s11682-021-00451-6. PMID:33634348. IF: 3,224
Sampedro F, Kulisevsky J. Intracortical surface-based MR diffusivity to investigate neurologic and psychiatric disorders: a review. JOURNAL OF NEUROIMAGING. 2022; 32(1). DOI:10.1111/jon.12930. PMID:34506674. IF: 3,870
Sampedro F, Marin J, Martinez S, Camacho V, Lopez DA, Pagonabarraga J, Kulisevsky J. Extrastriatal SPECT-DAT uptake correlates with clinical and biological features of de novo Parkinson’s disease. NEUROBIOLOGY OF AGING. 2021; 97. DOI:10.1016/j.neurobiolaging.2020.10.016. PMID:33212336. IF: 5,133
Sampedro F, Martinez S, Perez J, Perez R, Horta A, Campolongo A, Aracil I, Gomez B, Kulisevsky J. Interaction between sex and neurofilament light chain on brain structure and clinical severity in Huntington’s disease. Annals of Clinical and Translational Neurology. 2021; 8(12). DOI:10.1002/acn3.51460. PMID:34761569. IF: 5,430
Sampedro F, Perez J, Martinez S, Perez R, Horta A, Campolongo A, Izquierdo C, Pagonabarraga J, Gomez B, Kulisevsky J. Cortical microstructural correlates of plasma neurofilament light chain in Huntington’s disease. PARKINSONISM & RELATED DISORDERS. 2021; 85. DOI:10.1016/j.parkreldis.2021.03.008. PMID:33770670. IF: 4,402
Sampedro F, Roldan A, Alonso A, Grasa E, Portella MJ, Aguilar EJ, Nunez F, Gomez B, Corripio I. Grey matter microstructural alterations in schizophrenia patients with treatment-resistant auditory verbal hallucinations. JOURNAL OF PSYCHIATRIC RESEARCH. 2021; 138. DOI:10.1016/j.jpsychires.2021.03.037. PMID:33852993. IF: 5,250
Santos D, Fonticoba TD, Bartolome CC, Castro ES, Jesus S, Mir P, Pascual B, Pagonabarraga J, Kulisevsky J, Hernandez J, Planellas LL, Cabo I, Seijo M, Legarda I, Padilla FC, Caballol N, Cubo E, Nogueira V, Losada M, Ariztegui NL, Aramburu IG, Caldentey JG, Borrue C, Valero C, Alonso PS. Depression is Associated with Impulse-compulsive Behaviors in Parkinson’s disease. JOURNAL OF AFFECTIVE DISORDERS. 2021; 280. DOI:10.1016/j.jad.2020.11.075. PMID:33242731. IF: 6,533
Santos-Garcia D, Blazquez M, Calopa M, Escamilla F, Freire E, Ruiz PJG, Grandas F, Kulisevsky J, Lopez L, Castrillo JCM, Mir P, Pagonabarraga J, Perez F, Salom JM, Tijero B, Valldeoriola F, Yanez R, Aviles A, Luquin MR. Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project. Brain Sciences. 2021; 11(8):1027. DOI:10.3390/brainsci11081027. PMID:34439646. IF: 3,333
Santos-García D, Castro ES, de Deus Fonticoba T, Panceiras MJF, Enriquez JGM, González JMP, Bartolomé CC, Planellas LL, Caldentey JG, Caballol N, Legarda I, López IC, Manzanares LL, Rivera MAÁ, Catalán MJ, Nogueira V, Borrué C, Sauco MÁ, Vela L, Cubo E, Castrillo JCM, Alonso PS, Losada MGA, Ariztegui NL, Gastón MI, Kulisevsky J, Pagonabarraga J, et al. Sleep Problems Are Related to a Worse Quality of Life and a Greater Non-Motor Symptoms Burden in Parkinson’s Disease. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY. 2021;34(6):642-658. DOI:10.1177/0891988720964250. PMID: 33043810. IF: 2,718
Santos-García D, De Deus FT, Cores BC, Valdés AL, Suárez CE, Aneiros Á, Jesús S, Aguilar M, Pastor P, Planellas L, Cosgaya M, García CJ, Caballol N, Legarda I, Hernández VJ, Cabo I, López ML, González AI, Ávila RMA, José CM, Nogueira V, Puente V, García MJM, Borrué C, Solano VB, Álvarez SM, Vela L, Escalante S, Cubo E, Carrillo PF, Martínez CJC, et al.; COPPADIS Study Group [Kulisevsky J]. Mood in Parkinson’s disease: From early- to late-stage disease. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2021;36(5):627-646. DOI:10.1002/gps.5461. PMID: 33169885. IF: 3,850
Santos-Garcia D, Fonticoba TD, Cores C, Munoz G, Gonzalez JMP, Miro CM, Suarez E, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Vara JH, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Catalan MJ, Nogueira V, Puente V, de Arcos MR, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, Padilla FC, et al. [Kulisevsky J]. Predictors of clinically significant quality of life impairment in Parkinson’s disease. NPJ Parkinsons Disease. 2021; 7(1):118. DOI:10.1038/s41531-021-00256-w. PMID:34916528. IF: 9,304
Santos-Garcia D, Fonticoba TDD, Gonzalez JMP, Bartolome CC, Aymerich LV, Enriquez JGM, Suarez E, Jesus S, Aguilar M, Pastor P, Planellas LL, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Vara JH, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Catalan MJ, Nogueira V, Puente V, Moreno JMG, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, et al.; COPPADIS GRP [Kulisevsky J. Staging Parkinson’s Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life. Parkinsons Disease. 2021; 2021. DOI:10.1155/2021/8871549. PMID:34094501. IF: 3,170
Santos-Garcia D, Rios LN, Fonticoba TD, Bartolome CC, Roca LG, Painceiras MF, Miro CM, Canfield H, Jesus S, Aguilar M, Pastor P, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Vara JH, Cabo I, Manzanares LL, Aramburu IG, Rivera M, Mayordomo VG, Nogueira V, Puente V, Dotor J, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, Padilla FC, et al. [Kulisevsky J]. Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Diagnostics. 2021; 11(12):2380. DOI:10.3390/diagnostics11122380. PMID:34943619. IF: 3,992
Santos-García D, de Deus T, Cores C, Canfield H, Paz González JM, Martínez Miró C, Valdés Aymerich L, Suárez E, Jesús S, Aguilar M, Pastor P, Planellas L, Cosgaya M, García Caldentey J, Caballol N, Legarda I, Hernández-Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Catalán MJ, Nogueira V, Puente V, Dotor J, Borrué C, et al.; Coppadis Study Group [Kulisevsky J]. Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson’s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine. 2021; 11(7):626. DOI:10.3390/jpm11070626. PMID:34209166. IF: 3,508
Stantonyonge N, Martinez S, Sampedro F, Sanchez MB, Chico A. Defective involuntary attention to novelty in type 1 diabetes and impaired awareness of hypoglycaemia. DIABETES RESEARCH AND CLINICAL PRACTICE. 2021; 177:108898. DOI:10.1016/j.diabres.2021.108898. PMID:34098058. IF: 8,180
Stantonyonge N, Sampedro F, Mendez J, Martinez S, Chico A, Gomez B. Structural Gray and White Matter Differences in Patients With Type 1 Diabetes and Impaired Awareness of Hypoglycemia. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2021; 106(2). DOI:10.1210/clinem/dgaa832. PMID:33180907. IF: 6,134
Storm CS, Kia DA, Almramhi MM, Bandres S, Finan C, Hingorani AD, Wood NW, Clarimón J, Dols O, Kulisevsky J, Marín J, Pagonabarraga J, Lynch TL. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome. Nature Communications. 2021; 12(1):7342. DOI:10.1038/s41467-021-26280-1. PMID:34930919. IF: 17,694

NEUROLOGICAL DISEASES, NEUROSCIENCE & MENTAL HEALTH

Parkinson Disease and Movement Disorders

Main lines of research

Cognitive Impairment and Behavioural Dysfunctions in Parkinson Disease

Essential Tremor and Other Movement Disorders

Translational Research – Parkinsonian Animal Models

Translational Research – Cell Models

Huntington Disease

Progresive Supranuclear Palsy

Challenges

Cognitive and Behavioural Dysfunctions in Parkinson Disease

Huntington’s Disease

Essential Tremor and Other Movement Disorders

Translational Research – Animal Models of Parkinsonism

Group coordination

Members

Publications 2022

Publications 2021

Main lines of research

Cognitive Impairment and Behavioural Dysfunctions in Parkinson Disease

Essential Tremor and Other Movement Disorders

Translational Research – Parkinsonian Animal Models

Translational Research – Cell Models

Huntington Disease

Progresive Supranuclear Palsy

Challenges

Cognitive and Behavioural Dysfunctions in Parkinson Disease

Huntington’s Disease

Essential Tremor and Other Movement Disorders

Translational Research – Animal Models of Parkinsonism

Group coordination

Members

Publications 2022

Publications 2021

Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau